Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Esteban, E.
Right arrow Articles by Lacave, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esteban, E.
Right arrow Articles by Lacave, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1640-1647, 2003
© 2003 European Society for Medical Oncology

Original Paper

Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

E. Esteban+, L. González de Sande, Y. Fernández, N. Corral, J Fra, I. Muñiz, J. M. Vieitez, I. Palacio, J. L. Fernández, E. Estrada and A. J. Lacave

Servicio de Oncología Médica, Hospital Central de Asturias, Oviedo, Asturias, Spain

Received 9 February 2003; revised 19 June 2003; accepted 8 August 2003

Background:

Docetaxel and paclitaxel have activity in the second-line treatment of non-small-cell lung cancer (NSCLC), and can be administered as weekly schedules. This phase II randomised study was designed to test the efficacy and toxicity of both taxanes in patients with NSCLC previously treated with platinum-based chemotherapy.

Patients and methods:

Patients (n = 71) with documented NSCLC were randomised to receive docetaxel (n = 35 patients; 36 mg/m2) or paclitaxel (n = 36 patients; 80 mg/m2) as a 1 h weekly infusion for 6 weeks followed by a 2-week rest. The cycles were repeated until disease progression or non-acceptable toxicities occurred.

Results:

Treatment achieved partial response of one versus five patients, median time-to-progression of 74 versus 68 days, and overall survival of 184 versus 105 days, with docetaxel and paclitaxel, respectively. The most common non-haematological toxicities were (docetaxel versus paclitaxel): grade 3/4 pulmonary toxicity in seven versus one patient; grade 2/3 diarrhoea in nine versus five; and grade 3/4 haematological toxicities occurred in two versus four patients. There were no treatment-related deaths.

Conclusions:

Docetaxel and paclitaxel administered weekly have discrete efficacy in patients with NSCLC previously treated with platinum-based chemotherapy. The higher non-haematological toxicity of docetaxel, particularly pulmonary toxicity and diarrhoea, is of concern and warrants further investigation.

Key words: docetaxel, NSCLC, paclitaxel, second-line therapy, weekly administration


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
J-P. Sculier and D. Moro-Sibilot
First- and second-line therapy for advanced nonsmall cell lung cancer
Eur. Respir. J., April 1, 2009; 33(4): 915 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Sculier, J. Lafitte, J Lecomte, C. Alexopoulos, O Van Cutsem, V Giner, A Efremidis, M. Berchier, T Collon, A. Meert, et al.
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer
Ann. Onc., June 1, 2007; 18(6): 1037 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Y.-M. Chen, J.-F. Shih, R.-P. Perng, C.-M. Tsai, and J. Whang-Peng
A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based Chemotherapy.
Chest, April 1, 2006; 129(4): 1031 - 1038.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Camps, B. Massuti, A. Jimenez, I. Maestu, R. G. Gomez, D. Isla, J. L. Gonzalez, D. Almenar, A. Blasco, R. Rosell, et al.
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial
Ann. Onc., March 1, 2006; 17(3): 467 - 472.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Schuette, S. Nagel, T. Blankenburg, C. Lautenschlaeger, K. Hans, E.-W. Schmidt, I. Dittrich, H. Schweisfurth, L. F. von Weikersthal, A. Raghavachar, et al.
Phase III Study of Second-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel
J. Clin. Oncol., November 20, 2005; 23(33): 8389 - 8395.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. M. McDaid, L. Lopez-Barcons, A. Grossman, M. Lia, S. Keller, R. Perez-Soler, and S. Band Horwitz
Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human Heterotransplants
Cancer Res., April 1, 2005; 65(7): 2854 - 2860.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.